Our friends at Insight Pharma Reports created an exclusive deal, just for EpiGenie readers: Get 25% off of their new epigenetics report. This is a must have for anyone that needs to stay in tune with the epigenetics research market. There, now don’t you feel special?
Epigenetics: Emerging Targets, Available Technologies, Expert Interviews, and an Epigenetic Community Perspective
Newly published from Insight Pharma Reports, Epigenetics: Emerging Targets, Available Technologies, Expert Interviews, and an Epigenetic Community Perspective, covers several technologies, epigenetic targets, and market outlook. The first part of this report covers necessary background information, mostly pertaining to epigenetic targets, and the reasons they are being investigated. Several companies have kindly disclosed several strategies, methods, and techniques that they use for either target identification or technology development.
Report Features Include:
- Insight Pharma Reports polled a survey which had more than 150 responses. Specific areas highlighted are targets under investigation, market outlook, and how partnerships with external organizations have advanced the industry
- Interviews with CEOs, CSOs, and Expert Scientists from Constellation Pharmaceuticals, Epizyme Inc., and EpiTherapeutics, Active Motif, Cayman Chemical, and Reaction Biology
- Company background information
- Specific pharmaceutical/biopharmaceutical companies and their strategies
For more information, visit: www.InsightPharmaReports.com/Epigenetics-Report or contact Kerri Simpson at ksimpson@InsightPharmaReports.com
Make sure to mention keycode IPR25 when registering to save 25% off this report. (Valid only on new purchases of the Epigenetics: Emerging Targets, Available Technologies, Expert Interviews, and an Epigenetic Community Perspective Report)